Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-43 in Refractory Solid Tumors
NCT03443622Phase 1Withdrawn
- Sponsor
- SupremeCure Pharma
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of SC-43 in solid tumor (6 arms), sponsored by SupremeCure Pharma. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start May 2021; status: withdrawn.
02
Drugs
SC-43
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03443622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443622.